Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results

[1]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[2]  C. Catalano,et al.  Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards. , 2019, Journal of vascular and interventional radiology : JVIR.

[3]  S. Kakizaki,et al.  Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma , 2018, World journal of hepatology.

[4]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[5]  B. Sangro,et al.  Numerical zero‐dimensional hepatic artery hemodynamics model for balloon‐occluded transarterial chemoembolization , 2018, International journal for numerical methods in biomedical engineering.

[6]  P. Pereira,et al.  Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System , 2017, CardioVascular and Interventional Radiology.

[7]  Yoshiyuki Suzuki,et al.  Usefulness and limitations of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  Yoshinobu Yamamoto,et al.  Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short‐term results , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  Hiroshi Honda,et al.  Hemodynamic changes under balloon occlusion of hepatic artery: predictor of the short-term therapeutic effect of balloon-occluded transcatheter arterial chemolipiodolization using miriplatin for hepatocellular carcinoma , 2016, SpringerPlus.

[10]  T. Kamoshida,et al.  Selective balloon‐occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: Retrospective comparison with conventional super‐selective TACE , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  H. Kitagaki,et al.  Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma , 2016, CardioVascular and Interventional Radiology.

[12]  T. Murakami,et al.  Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience , 2015, Oncology.

[13]  S. Kakizaki,et al.  Safety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  Tomohiro Matsumoto,et al.  Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations , 2015, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

[15]  Jin-Young Choi,et al.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. , 2014, Radiology.

[16]  T. Ishikawa,et al.  Predictive Factor of Local Recurrence after Balloon-Occluded TACE with Miriplatin (MPT) in Hepatocellular Carcinoma , 2014, PloS one.

[17]  C. Bartolozzi,et al.  Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma , 2014, British Journal of Cancer.

[18]  Fengyong Liu,et al.  Bile Duct Injury after Transcatheter Arterial Chemoembolization: Risk Factors and Clinical Implications. , 2014, Hepato-gastroenterology.

[19]  Y. Imai,et al.  Hemodynamic changes during balloon-occluded transarterial chemoembolization (B-TACE) of hepatocellular carcinoma observed by contrast-enhanced ultrasound , 2014, Journal of Medical Ultrasonics.

[20]  E. Basch,et al.  A pilot study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in a phase I clinical trial. , 2013 .

[21]  M. Gonen,et al.  Pattern of Retained Contrast on Immediate Postprocedure Computed tomography (CT) After Particle Embolization of Liver Tumors Predicts Subsequent Treatment Response , 2013, CardioVascular and Interventional Radiology.

[22]  N. Takahashi,et al.  Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon-occluded Arterial Stump Pressure , 2013, CardioVascular and Interventional Radiology.

[23]  V. Mazzaferro,et al.  EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .

[24]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[25]  C. Bartolozzi,et al.  Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. , 2011, Journal of vascular and interventional radiology : JVIR.

[26]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[27]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[28]  A. Gasbarrini,et al.  Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. , 2010, World journal of gastroenterology.

[29]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[30]  D. Lu,et al.  Liver Transplantation Criteria For Hepatocellular Carcinoma Should Be Expanded: A 22-Year Experience With 467 Patients at UCLA , 2007, Annals of surgery.